Aflofarm’s strategic goal is dynamic product development.

In order to meet therapeutic needs, in the interests of patient’s health and quality of life, we introduce new products based on the latest knowledge and innovative technologies.

The process of designing new products is based largely on our own studies. The Research & Development Department employs highly qualified staff, acting as a creative team, motivated to achieve their goals.

The laboratory is equipped with a full range of modern technological equipment, which enables the development of high-tech products in solid, semi-solid, and liquid forms (tablets, coated tablets, dragées, hard gelatine capsules, granules, powders, creams, ointments, gels, suspensions, syrups, drops).

We define quality parameters for new products using the most modern apparatuses, with which our analytical laboratory is equipped.

Documentation for our products meets the stringent formal and legal requirements appropriate to the category. We conduct design processes for medicinal products, medical devices, dietary supplements, and cosmetics.

We perform design work on new products in cooperation with scientific institutions and experts.

We also introduce products based on licenses acquired from domestic and foreign partners.

The Research & Development Department uses a system that is in accordance with standards PN-EN-ISO 9001, BS EN ISO 14001, ISO 22000, EN ISO 13485, BS N 18001 and GMP, while the analytical laboratory operates in accordance with GLP principles.

Social Responsibility at Aflofarm manifests the desire to provide patients with broad access to modern, effective, and safe products. We strive to fulfil the needs of patients, doctors, and pharmacists by introducing innovative solutions.

Out of concern for the quality and safety of pharmacotherapy’s youngest patients, we introduced Poland’s first paediatric pharmaceutical medicine that is antiviral and increases resistance – Neosine (inosinum pranobexum) syrup.

With the aim of improving patient access to safe and effective pharmacotherapy, we were the first to launch on the Polish market the analgesic and anti-inflammatory medicinal product Opokan, tablets, 7.5 mg (meloxicam) in the non-prescription medicine category (OTC).